Efficacy and safety of Bosutinib in Patient with Chronic myeloid
leukemia who was intolerant to DASTANIB,NILOTUNIB -Case report
- Abdullah Mohammad Arshad
, - mohamed yassin
Abdullah Mohammad Arshad
Hamad Medical Corporation
Corresponding Author:aarshad1@hamad.qa
Author ProfileAbstract
Bosutinib is approved as first line therapy for treatment of chronic
phase CML and also in patients who are either resistant or intolerant to
previous TKI. We present a 59 year old male who was intolerant to 2 TKI
but showed excellent hematological and major molecular response to
Bosutinib.
